QURE UNIQURE NV

uniQure to Participate at Multiple Upcoming Conferences

uniQure to Participate at Multiple Upcoming Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 30, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in September:

• Wells Fargo Securities 2018 Healthcare Conference, September 5 – 6, 2018 at the Westin Copley Place in Boston, MA.  

  • Matt Kapusta, chief executive officer at uniQure, will present a corporate update on Wednesday, September 5th at 3:35 p.m. ET. The live webcast can be accessed through the link displayed in the . The webcast replay will be available for at least 72 hours following the live event.
  • In addition, company management will host meetings with institutional investors. 

• Citi’s 13th Annual Biotech Conference, September 5 – 6, 2018 at the Four Seasons Hotel in Boston, MA.  

  • Matt Kapusta will participate in a panel discussion entitled, “Gene Therapy: Present & Future”, moderated by Citi analysts, on Thursday, September 6th at 10:00 a.m. ET. The live webcast can be accessed through the link displayed in the . The webcast replay will be available for at least 72 hours following the live event.
  • In addition, company management will host meetings with institutional investors. 

• Goldman Sachs 8th Annual Biotech Symposium, September 7, 2018 at Goldman Sachs London Offices, in London, United Kingdom.  

  • Sander van Deventer, M.D., Ph.D., chief scientific officer at uniQure, will be available for one-on-one meetings with institutional investors on Friday, September 7th.  

• 2018 Janney Healthcare Conference, September 17, 2018 at the Union League Club in New York City.   

  • Sander van Deventer, M.D., Ph.D., chief scientific officer, will present a corporate update on Monday, September 17th at 10:45 a.m. ET.
  • In addition, company management will host meetings with institutional investors.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with liver/metabolic, central nervous system and cardiovascular diseases.

uniQure Contacts

For Investors:   For Media:  
       
Maria E. Cantor Eva M. Mulder Tom Malone  
Direct: 339-970-7536 Direct:  Direct:  339-970-7558  
Mobile: 617-680-9452 Mobile: 79 Mobile:  339-223-8541  
     

EN
30/08/2018

Underlying

QUREUNIQURE NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UNIQURE NV

 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces 2025 Financial Results and Provides Recent Company U...

uniQure Announces 2025 Financial Results and Provides Recent Company Updates ~ Held Type A meeting with FDA to discuss AMT-130 for Huntington’s disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter of 2026 ~ ~ Completed enrollment of the first cohort in the Phase I/IIa study of AMT-260 in refractory mesial temporal lobe epilepsy, with additional clinical data expected in the first half of 2026 ~ ~ Presented updated Phase I/II data from AMT-191 in Fabry disease showing durable, dose-dependent increases in α-Gal ...

March 2, 2026 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the company received final meeting minutes from the U.S. Food and Drug Administration (FDA) regarding a Type A meeting held on January 30, 2026 to discuss AMT-130, an investigational gene therapy for Huntington’s disease (HD).   The FDA stated that it cannot agree that data from the Phase I/II studies, com...

March 2, 2026 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure to Announce 2025 Financial Results

uniQure to Announce 2025 Financial Results ~ uniQure to host earnings call on Monday, March 2, 2026 at 8:00 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report fourth quarter and full year of 2025 financial results before market open on Monday, March 2, 2026. Management will then host a conference call at 8:00 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at , and following t...

February 23, 2026 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing...

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease ~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~ ~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme replacement therapy status across all cohorts ~ ~ Six of 11 patients have discontinued enzyme replacement therapy as of data cutoff date ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 06, 2026 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene ...

February 6, 2026 1 EN
 PRESS RELEASE
Free
QURE UNIQURE NV

uniQure Announces Type A Meeting Scheduled with FDA

uniQure Announces Type A Meeting Scheduled with FDA LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Biologics License Application (BLA) data package to support accelerated approval of AMT-130, the Company’s investigational gene therapy for the treatment of Huntington’s disease. “We look forward to a constructive discussion with th...

January 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch